Date: 2017-06-09

Type of information: Development agreement

Compound: insulin management solutions.

Company: Ascensia Diabetes Care (Switzerland) Voluntis (France)

Therapeutic area: Metabolic diseases

Type agreement: development

Action mechanism: Insulia® Diabetes Management Companion is a prescription-only medical device that provides people with type 2 diabetes with insulin dose recommendations and educational coaching messages, through a smartphone app, based on blood glucose values and other diabetes-related data. Insulia® supports a wide variety of treatment plan configurations and evidence-based insulin adjustment rules used in routine clinical practice. The personalized treatment plan is initially set-up by the healthcare professional, based on an individual's profile, insulin prescription and blood glucose targets. The dose adjustment algorithm is embedded in the app requiring no further validation from healthcare professionals after the system's initial setup. The patient data can then be automatically shared with the healthcare team, who can remotely monitor the patient's progress toward their goal thanks to tailored notifications. The solution has received both FDA 510(k) clearance from the US FDA and CE Mark approval in Europe in November 2016. The Contour®Next One and Contour® Plus One systems each feature a highly accurate easy-to-use blood glucose smart meter that links to a mobile device via Bluetooth® connectivity. The meter connects to the Contour® Diabetes app, a mobile app that collects, stores and analyzes patient blood glucose measurements delivered to it by the meter. The Contour®Next One and Contour® Plus One BGMSs received CE Mark approval in Europe in April 2016, and the Contour® Next One BGMS received 510(k) clearance from the FDA in November 2016.

Disease: type 2 diabetes


  • • On June 9, 2017, Ascensia Diabetes Care and Voluntis announced a global technology partnership designed to help improve the lives of people with type 2 diabetes by optimizing insulin management. This collaboration will connect the Voluntis basal insulin management solution for people with type 2 diabetes, the Insulia® Diabetes Management Companion, with the Contour®Next One and Contour®Plus One blood glucose monitoring systems (BGMS) from Ascensia.
  • Under the terms of the agreement, the Contour®Next One and Contour®Plus One meters will connect via Bluetooth to Insulia® and the blood glucose readings will be used to calculate basal insulin dosing for people with type 2 diabetes.
  • By linking highly accurate blood glucose data to this basal insulin manager, the two companies aim to empower self-management for patients and help optimize insulin management in the real-world to improve outcomes. The integration between these two solutions is expected to be available for people with diabetes and healthcare professionals in Q4 2017.

Financial terms:

Latest news:

Is general: Yes